Data from the phase 3b STEP UP trial demonstrate that the 7.2 mg semaglutide dose provides superior weight reduction compared ...

In his complaint, Michael Wade Nance said his veins were so severely compromised that they were likely to blow and cause him ...

Novo Nordisk today announced US Food and Drug Administration (FDA) approval of a new higher dose of Wegovy®, Wegovy® HD (semaglutide) injection 7.2 mg, which demonstrated substantial weight loss in ...

Early data from the first phase III trial of Lilly’s triple agonist show reductions in weight and HbA1c for patients with ...

IN THE SEMICONDUCTOR industry, Arm is everywhere and nowhere. Designs from the British-based, American-listed, Japanese-controlled firm sit in almost all the world’s smartphones and most other ...

Many people living with rheumatoid arthritis (RA) rely on long-term medications to manage joint pain, stiffness, and inflammation. A number of these treatments are given as subcutaneous injections, ...

Arm topped estimates on the top and bottom lines in its Q3 earnings report. The company warned that smartphone royalty growth could slow next year. Royalty rates continue to move higher is it invests ...

Mounjaro (tirzepatide) is prescribed to manage blood sugar levels in people with type 2 diabetes. It’s available as a single-dose prefilled pen. You will administer your Mounjaro injections into your ...

Subcutaneous (SC) formulations of monoclonal antibodies are rapidly transforming the delivery of cancer immunotherapy. Designed to replace or complement intravenous (IV) administration, SC delivery ...

Arm Holdings reported strong growth in both licensing and royalties. Its Compute Subsystems business has been gaining steam. However, the stock's valuation could put downward pressure on the shares.

For anyone managing bipolar 1 disorder, staying consistent with daily medication can be a challenge. Busy schedules, shifting moods, and side effects can make it easy to miss doses — and even brief ...

Monday - Friday, 6:00 - 7:00 PM ET Arm Holdings CEO Rene Haas discussed artificial intelligence technology's energy use in an interview with CNBC's Jim Cramer. He suggested that over time, a large ...